Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Moderate Buy” by Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $16.88.

Several research firms recently commented on FOLD. JPMorgan Chase & Co. increased their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Jefferies Financial Group started coverage on Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. Cantor Fitzgerald lifted their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Finally, Morgan Stanley restated an “equal weight” rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th.

Amicus Therapeutics Stock Up 0.7 %

Amicus Therapeutics stock opened at $9.80 on Friday. The firm has a 50 day moving average price of $10.49 and a 200-day moving average price of $10.61. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.57. The company has a market capitalization of $2.93 billion, a P/E ratio of -28.82 and a beta of 0.60.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $11.46, for a total transaction of $85,950.00. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at $10,161,054.84. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 30,401 shares of company stock valued at $339,363. 2.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Amicus Therapeutics

Several institutional investors have recently modified their holdings of the company. OLD Second National Bank of Aurora purchased a new position in shares of Amicus Therapeutics in the third quarter worth about $26,000. Hazlett Burt & Watson Inc. boosted its holdings in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares in the last quarter. Blue Trust Inc. grew its holdings in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares during the period. Arcadia Investment Management Corp MI purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $32,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Amicus Therapeutics during the third quarter valued at $55,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.